 CD30 TNFRSF8 is a transmembrane glycoprotein of the tumor necrosis factor receptor TNFR superfamily, and it is involved in signal transduction via the activation of the NF-κB pathway and the mitogen-activated protein kinases MAPKs, ultimately modulating cell growth, proliferation and apoptosis. CD30 is a non-lineage-specific activation marker expressed by scattered B and T immunoblasts. In addition, a subset of cases in virtually all T-cell lymphoma entities may also express CD30 but at variable and generally lower levels. In fact, a recent study in 22 patients with extranodal NKT-cell lymphoma showed 75 of positive rate of CD30 expression 75. Moreover, CD30 expression was also documented in the tumor sample of EB virus positive diffuse large B-cell lymphomas EBV DLBCL of the elderly 28.9, 1138. Therefore, Brentuximab vedotin may have potential benefits for patients with CD30-positive NHL other than anaplastic large cell lymphoma such as CD30-positive PTCLs, NOS. Considering the role of CD30 in signal transduction pathway associated with tumor growth and proliferation, its expression may be associated with tumor aggressiveness. In accordance with this, it is more likely that relapse or refractory NHLs may have CD30 expression, and the potential benefits of this promising agent as a salvage therapy deserve to be further investigated in these patients who have high risk of treatment failure. Thus, we designed a phase II study for relapsed or refractory NHL patients. This study is to explore the safety and activity of dosing once every 3 weeks of Brentuximab vedotin in patients with relapsed or refractory CD30-positive NHL other than anaplastic large cell lymphoma. 